{"id":"medium-dose-pf-07328948","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Atazanavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Cobicistat","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Darunavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Lopinavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Ritonavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Saquinavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tipranavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Fosamprenavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Indinavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Etravirine","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Nelfinavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Rilpivirine","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Efavirenz","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Lamivudine","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Zidovudine","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Abacavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Emtricitabine","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir alafenamide","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir disoproxil fumarate","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir disoproxil","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir fumarate","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir alafenamide fumarate","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir alafenamide","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir disoproxil fumarate","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir disoproxil","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir fumarate","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir alafenamide fumarate","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir alafenamide","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir disoproxil fumarate","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir disoproxil","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir fumarate","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir alafenamide fumarate","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir alafenamide","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir disoproxil fumarate","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir disoproxil","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir fumarate","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir alafenamide fumarate","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir alafenamide","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir disoproxil fumarate","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir disoproxil","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir fumarate","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir alafenamide fumarate","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir alafenamide","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir disoproxil fumarate","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir disoproxil","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir fumarate","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir alafenamide fumarate","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir alafenamide","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir disoproxil fumarate","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir disoproxil","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir fumarate","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir alafenamide fumarate","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir alafenamide","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir disoproxil fumarate","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir disoproxil","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir fumarate","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir alafenamide fumarate","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir alafenamide","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir disoproxil fumarate","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir disoproxil","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir fumarate","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir alafenamide fumarate","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir alafenamide","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir disoproxil fumarate","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir disoproxil","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir fumarate","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir alafenamide fumarate","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir alafenamide","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir disoproxil fumarate","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir disoproxil","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir fumarate","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir alafenamide fumarate","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir alafenamide","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir disoproxil fumarate","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir disoproxil","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir fumarate","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir alafenamide fumarate","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir alafenamide","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir disoproxil fumarate","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir disoproxil","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir fumarate","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir alafenamide fumarate","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir alafenamide","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir disoproxil fumarate","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir disoproxil","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir fumarate","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir alafenamide fumarate","action":"Monitor","effect":"Decreased antiviral activity"}],"commonSideEffects":[],"contraindications":["History of clinically significant hypersensitivity reactions to the active ingredients (nirmatrelvir or ritonavir) or any other components.","Co-administration with drugs highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions.","Co-administration with potent CYP3A inducers where significantly reduced nirmatrelvir or ritonavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance.","PAXLOVID is not recommended in patients with severe hepatic impairment (Child-Pugh Class C).","The concomitant use of PAXLOVID and certain other drugs may result in potentially significant drug interactions.","Hypersensitivity Reactions: Anaphylaxis, serious skin reactions (including toxic epidermal necrolysis and Stevens-Johnson syndrome) may occur in patients receiving PAXLOVID.","Hepatotoxicity: Hepatic transaminase elevations, clinical hepatitis, and jaundice have been observed in patients receiving PAXLOVID.","Co-administration with eplerenone is contraindicated due to potential for serious and/or life-threatening reactions in patients with renal and/or hepatic impairment.","Co-administration with colchicine is contraindicated due to potential for serious and/or life-threatening reactions in patients with renal and/or hepatic impairment.","Co-administration with atazanavir, darunavir, and tipranavir is contraindicated due to potential loss of virologic response and possible resistance.","Co-administration with lurasidone and pimozide is contraindicated due to potential for serious and/or life-threatening reactions."],"specialPopulations":{"Pregnancy":"None","Geriatric use":"18-80 years","Paediatric use":"None","Renal impairment":"Groups 2 & 3 only: chronic renal impairment, defined by the following mean eGFR criteria (based on screening visits): - Severe RI: 15 ≤ mean eGFR <30 mL/min, not requiring hemodialysis. - Moderate RI: 30 ≤ mean eGFR <60 mL/min.","Hepatic impairment":"None"}},"trials":["NCT06991257"],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=medium-dose-pf-07328948","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-05-16T02:25:21.457346+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:40:16.268833+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=medium-dose-pf-07328948","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:40:17.905718+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2108659/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:40:18.821875+00:00"}},"allNames":"medium dose pf-07328948","offLabel":[],"timeline":[],"aiSummary":"Medium Dose PF-07328948 is being studied in a clinical trial for the treatment of heart failure. The trial, titled \"A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF),\" is a phase 2, randomized, double-blind, placebo-controlled study.","brandName":"Medium Dose PF-07328948","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Unknown","novelty":"Unknown","modality":"Unknown","drugClass":"Unknown","explanation":"","oneSentence":"","technicalDetail":"The technical details of PF-07328948's mechanism of action are not available. As a result, healthcare professionals cannot provide a detailed explanation of how the drug works. More information is required to understand its pharmacological properties."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"yoyGrowth":"+7%","annualCostUS":"$80,000/yr","genericStatus":"Generic — off-patent","currentRevenue":"","patientPopulation":"~","peakSalesEstimate":"$21.2B"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=medium-dose-pf-07328948","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=medium-dose-pf-07328948","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_emaChecked":true,"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-05-16T02:25:21.457698+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"PF-06481622","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"},{"name":"PF-06650808","company":"Pfizer","advantage":"Competes with medium-dose PF-07328948 in BDK inhibition"}],"dataSources":[{"url":"https://tavily.com","name":"Tavily AI Search","fields":["latestUpdates"],"retrievedDate":"2026-04-07"},{"url":"https://jina.ai/reader","name":"Jina Reader","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"},{"url":"https://groq.com","name":"Groq (Llama 3.1 8B)","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"}],"genericName":"medium-dose-pf-07328948","indications":{"approved":[{"name":"COVID-19","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06991257","phase":"PHASE2","title":"A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)","status":"RECRUITING","sponsor":"Pfizer","isPivotal":false,"enrollment":620,"indication":"Heart Failure","completionDate":"2027-12-14","primaryEndpoint":""}],"genericFilers":[],"latestUpdates":[{"url":"https://s206.q4cdn.com/795948973/files/doc_financials/2025/q3/Q3-2025-Earnings-Charts-FINAL.pdf","date":"2026-04-07","type":"news","title":"[PDF] Q3 2025 Earnings Charts","source":"s206.q4cdn.com"},{"url":"https://www.nasdaq.com/press-release/pfizer-reports-solid-full-year-2025-results-and-reaffirms-2026-guidance-2026-02-03","date":"2026-04-07","type":"news","title":"Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 ...","source":"www.nasdaq.com"},{"url":"https://s206.q4cdn.com/795948973/files/doc_financials/2025/q4/Q4-2025-PFE-Earnings-Release-FINAL2.pdf","date":"2026-04-07","type":"news","title":"[PDF] Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 ...","source":"s206.q4cdn.com"},{"url":"https://cdn.pfizer.com/pfizercom/product-pipeline/Q1_2025_Pipeline_Update_29APR2025.pdf?VersionId=7hjVCBiYrHhTyTEE1tgA5DD8Hp4qB0vo","date":"2026-04-07","type":"news","title":"[PDF] 5 - Pfizer Pipeline","source":"cdn.pfizer.com"},{"url":"https://cdn.pfizer.com/pfizercom/product-pipeline/Q4%202025%20Pipeline%20Update_vFinal3.pdf?VersionId=XSLcQ04JnYn3Py.PPsUP_5lAboV.fDPh","date":"2026-04-07","type":"news","title":"[PDF] Pfizer Pipeline","source":"cdn.pfizer.com"}],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL2108659","moleculeType":"Unknown","molecularWeight":""},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL2108659"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"commercialAnalysis":{"text":"Medium Dose PF-07328948 by Pfizer is a COVID-19 treatment with a mechanism of action not specified. As of the latest available data, Pfizer reported full-year 2025 revenues of $62.6 billion, reflecting a 2% year-over-year operational decline [1, s206.q4cdn.com, February 3, 2026]. Excluding contributions from Paxlovid and Comirnaty, revenues grew 6% operationally [1, s206.q4cdn.com, February 3, 2026]. The revenue trajectory for Medium Dose PF-07328948 is uncertain, as Pfizer does not provide specific revenue data for this product.\n\nThe competitive landscape for COVID-19 treatments is intense, with multiple players vying for market share. Pfizer's competitive position is bolstered by its strong late-stage pipeline, with approximately 20 key pivotal study starts planned for 2026 [1, s206.q4cdn.com, February 3, 2026]. However, the company faces threats from generic competition and emerging treatments from other manufacturers.\n\nKey upcoming catalysts for Medium Dose PF-07328948 include patent cliffs and potential label expansions. Pfizer has not disclosed specific patent expiration dates for this product. Additionally, the company's pipeline competitors, such as mRNA-based treatments, may pose a threat to Medium Dose PF-07328948's market share.\n\nThe market outlook for COVID-19 treatments is uncertain, with the pandemic's impact on global healthcare systems and economies still evolving. As Pfizer continues to invest in its late-stage pipeline, the company may be well-positioned to capitalize on growth opportunities in the COVID-19 treatment market. However, the competitive landscape and regulatory environment will continue to shape the market trajectory for Medium Dose PF-07328948.","model":"llama-3.1-8b (Groq)","sources":[{"url":"https://s206.q4cdn.com/795948973/files/doc_financials/2025/q3/Q3-2025-Earnings-Charts-FINAL.pdf","date":"","title":"[PDF] Q3 2025 Earnings Charts","source":"s206.q4cdn.com"},{"url":"https://www.nasdaq.com/press-release/pfizer-reports-solid-full-year-2025-results-and-reaffirms-2026-guidance-2026-02-03","date":"","title":"Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 ...","source":"www.nasdaq.com"},{"url":"https://s206.q4cdn.com/795948973/files/doc_financials/2025/q4/Q4-2025-PFE-Earnings-Release-FINAL2.pdf","date":"","title":"[PDF] Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 ...","source":"s206.q4cdn.com"}],"disclaimer":"AI-generated analysis based on public sources. Verify with primary sources for investment decisions.","generatedDate":"2026-04-07"},"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Unknown","firstApprovalDate":"","enrichmentLevel":3,"visitCount":9,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-05-16T02:25:21.457698+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}